Apronal

Chemical compound

Apronal (brand name Sedormid), or apronalide, also known as allylisopropylacetylurea or allylisopropylacetylcarbamide, is a hypnotic/sedative drug of the ureide (acylurea) group synthesized in 1926 by Hoffmann-La Roche. Though it is not a barbiturate, apronal is similar in structure to the barbiturates (being an open-chain carbamide instead of having a heterocyclic ring).

Nº Q1095009 ★★

Poco común · Saberes

Apronal

Chemical compound

Texto en inglés

Apronal (brand name Sedormid), or apronalide, also known as allylisopropylacetylurea or allylisopropylacetylcarbamide, is a hypnotic/sedative drug of the ureide (acylurea) group synthesized in 1926 by Hoffmann-La Roche. Though it is not a barbiturate, apronal is similar in structure to the barbiturates (being an open-chain carbamide instead of having a heterocyclic ring).

Último precio

—

Precio mínimo

—

Mediana 7 d

—

Ventas 30 d

0

Rango 30 d

—

En circulación

0

Cotización

Ver tabla
Fechamediana MínMáxventas

Historial de ventas

Última venta
—
Media 30 d
—
Mínimo 30 d
—
Máximo 30 d
—
Ventas 7 d
0
Ventas 30 d
0

Aún no hay ventas.

Ventas anónimas: sin comprador ni vendedor. Las cifras solo cuentan ventas entre jugadores.

En Wikipedia

Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.

Apronal (brand name Sedormid), or apronalide, also known as allylisopropylacetylurea or allylisopropylacetylcarbamide, is a hypnotic/sedative drug of the ureide (acylurea) group synthesized in 1926 by Hoffmann-La Roche. Though it is not a barbiturate, apronal is similar in structure to the barbiturates (being an open-chain carbamide instead of having a heterocyclic ring). In accordance, it is similar in action to the barbiturates, although considerably milder in comparison (formerly used as a daytime sedative at doses of 1 to 2 grams every 3 to 4 hours). Upon the finding that it caused patients to develop thrombocytopenic purpura, apronal was withdrawn from clinical use. Medicines with apronal are no longer used except in Japan and South Korea. The Therapeutic Goods Administration issued a safety alert in May 2023 which prohibits the sale, supply and use of Japanese EVE-branded products in Australia due to its dangerous side effects.

Texto: Wikipedia en inglés, CC BY-SA 4.0. · Imagen: Fvasconcellos 02:48, 23 August 2007 (UTC) (Public domain) ·

Cartas cercanas

Ver la ficha

Confirmación